In addition to destroying the cancer cells by using the immune system, BCG also induces a high expression of PD-L1 on the surface of the tumor cells, which, in a certain way contributes to the unresponsiveness of patients to BCG (4). The gene discussed is CD274; the disease is neoplasm.